Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Other Accumulated Expenses (2016 - 2025)

Altimmune (ALT) has disclosed Other Accumulated Expenses for 8 consecutive years, with $177000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 227.78% to $177000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $177000.0, a 227.78% increase, with the full-year FY2024 number at $55000.0, down 55.65% from a year prior.
  • Other Accumulated Expenses was $177000.0 for Q3 2025 at Altimmune, down from $183000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $183000.0 in Q2 2025 to a low of $54000.0 in Q3 2024.
  • A 4-year average of $98555.6 and a median of $69000.0 in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 55.65% in 2024, then soared 227.78% in 2025.
  • Altimmune's Other Accumulated Expenses stood at $103000.0 in 2022, then increased by 20.39% to $124000.0 in 2023, then crashed by 55.65% to $55000.0 in 2024, then soared by 221.82% to $177000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Other Accumulated Expenses are $177000.0 (Q3 2025), $183000.0 (Q2 2025), and $56000.0 (Q1 2025).